Skip to content
Kalpvruksh Markets
Offline Log in

IPCALABNSEOffline

IPCA LABORATORIES · INE571A01038 · Mid Cap · #234
1,949.60−22.40 (−1.14%)last close · 05 Nov 2026
Prev close
1,972.00
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹38,683 cr
52-week range · to 05 Nov 20261,271.22,009.6

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

IPCALAB is 3% below its 52-week high, above its 200-day average, ahead of Healthcare by 9.4 pts over 3 months — a Mid Cap company, #234 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · 3% below its 52-week high
  • ahead of its industry by 9.4 pts over 3 months · rank 8 of 44 in Healthcare · +12.9% vs Nifty 500
  • traded value 1.6× usual · delivery 60% vs 53% usual
  • FPI +0.8 pp · DII −0.8 pp · MF schemes in Sept 2026: 49 bought, 46 cut · no promoter pledge · quarter ended 2026-09-30
  • Jun 2026 quarter: profit +72% year on year · revenue +21%
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹38,683 cr
Rank
#234
Cap band
Mid Cap
Nearest cut-off — Mid / Small
+13.14% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.5×
median 1,72,498
Delivered
2,59,962
Of volume
41%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+1.2%−4.4 pts—
1 month+0.2%−4.2 pts−3.6 pts
3 months+10.5%+12.9 pts+9.4 pts
6 months+24.6%+24.1 pts+12.4 pts
1 year+51.3%+55.3 pts—

Industry: Healthcare (Nifty 500 classification) · rank 8 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+1.4%
above
vs 50-day average
+0.2%
above
vs 200-day average
+15.8%
above
ATR (14)
3.9%
typical daily range
Volatility
27%
1 month, annualised
Beta
0.03
vs Nifty 500, 1 year
Traded value
1.6×
vs usual
Delivery
60%
usual 53%
From the 52-week high
−3.0%
place in range 92% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters44.7%44.7%44.7%44.7%
FPI10.6%10.6%10.7% +0.111.5% +0.8
Mutual funds30.5%31.2% +0.731.1% −0.131.1% −0.1
Other DII6.5%5.9% −0.65.9%5.2% −0.7
Individuals5.9%5.8% −0.15.8%5.7%
Others1.8%1.7%1.8%1.8%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
90,514
Individuals
85,249

Indian passive funds’ stake

2026-06-30

Of free float
0.77%
Of all shares
0.43%
Schemes
67
Days to unwind
3.5
at 100% of volume

10,86,201 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
156
67 index · 89 active
Bought more
79
Sold some
30
FundSharesChangeDid
Axis ESG Integration Strategy Fund-Reg(G)Active+52,439+346.0%bought
Bandhan Healthcare Fund-Reg(G)Active+25,000+250.0%bought
TRUSTMF Mid Cap Fund-Reg(G)Active+9,543+89.4%bought
UTI Mid Cap Fund-Reg(IDCW)Active−48,488−61.8%sold
DSP Flexi Cap Fund-Reg(IDCW)Active−4,88,932−51.6%sold
WOC Pharma and Healthcare Fund-Reg(G)Active−35,212−46.7%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 26134742415+0.6%₹11,310 cr
Aug 2613216612012−0.5%₹11,520 cr
Jul 26128834479−0.6%₹10,243 cr
Jun 261291152237−0.6%₹10,029 cr
May 26125249233−1.1%₹9,041 cr
Apr 26126654201+0.7%₹9,182 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 4 of 8 disclosures
0 selected
20 Aug 2025Paschim Chemicals Private LimitedPromoter GroupSell1,01,73,000₹00.00%Others
20 Aug 2025Mexin Medicaments Pvt. Ltd.Promoter GroupSell14,058₹00.00%Others
20 Aug 2025Kaygee Investments Private LimitedPromoter GroupBuy1,01,87,058₹025.49%Others
11 Mar 2024Paschim Chemicals Private LimitedPromoter GroupBuy35,000₹4.2 cr4.01%Market Purchase

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Board outcome
    IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
    05 Nov 2026
  • Board outcome
    IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    13 Aug 2026
  • Credit rating
    IPCA Laboratories Limited has informed the Exchange about Credit Rating
    07 Jul 2026
  • Board outcome
    IPCA Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2026.
    29 Jun 2026
  • Board outcome
    IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
    29 May 2026
  • Board outcome
    Outcome of Board Meeting-XBRL IPCA LABORATORIES LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 29-May-2026 for Dividend
    29 May 2026

IPCALAB: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹6Final07 Aug 202607 Aug 2026
EarlierDividend₹2Final05 Aug 202505 Aug 2025
EarlierDividend₹2Interim27 Nov 202427 Nov 2024
EarlierDividend₹2Final06 Aug 202407 Aug 2024
EarlierDividend₹2Interim22 Nov 202322 Nov 2023
EarlierDividend₹4Interim22 Nov 202223 Nov 2022
EarlierDividend₹8Interim22 Nov 202123 Nov 2021
EarlierBonus1:1—28 Jan 200531 Jan 2005

8 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.